A Design of Experiment Approach to Optimize Spray-Dried Powders Containing and Bacteriophages

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2021 Oct 26

PMID 34696356

Citations 5

Authors

Emilie Tabare

Tea Glonti

Christel Cochez

Cyrille Ngassam

Jean-Paul Pirnay

Karim Amighi

Jonathan Goole

Affiliations

Soon will be listed here.

Abstract

In the present study, we evaluated the effect of spray-drying formulations and operating parameters of a laboratory-scale spray-dryer on the characteristics of spray-dried powders containing two bacteriophages exhibiting different morphotypes: a podovirus (LUZ19) and a myovirus (14-1). We optimized the production process for bacteriophage-loaded powders, with an emphasis on long-term storage under ICH (international conference on harmonization) conditions. D-trehalose-/L-isoleucine-containing bacteriophage mixtures were spray-dried from aqueous solutions using a Büchi Mini Spray-dryer B-290 (Flawil, Switzerland). A response surface methodology was used for the optimization of the spray-drying process, with the following as-evaluated parameters: Inlet temperature, spray gas flow rate, and the D-trehalose/L-isoleucine ratio. The dried powders were characterized in terms of yield, residual moisture content, and bacteriophage lytic activity. L-isoleucine has demonstrated a positive impact on the activity of LUZ19, but a negative impact on 14-1. We observed a negligible impact of the inlet temperature and a positive correlation of the spray gas flow rate with bacteriophage activity. After optimization, we were able to obtain dry powder preparations of both bacteriophages, which were stable for a minimum of one year under different ICH storage conditions (up to and including 40 °C and 75% relative humidity).

Citing Articles

Isolation and Characterization of Two Novel Genera of Jumbo Bacteriophages Infecting Isolated from Agricultural Regions in Mexico.

Villicana C, Rubi-Rangel L, Amarillas L, Lightbourn-Rojas L, Carrillo-Fasio J, Leon-Felix J Antibiotics (Basel). 2024; 13(7).

PMID: 39061333 PMC: 11273794. DOI: 10.3390/antibiotics13070651.

Bacteriophage Production in Compliance with Regulatory Requirements.

Pirnay J, Merabishvili M, De Vos D, Verbeken G Methods Mol Biol. 2023; 2734:89-115.

PMID: 38066364 DOI: 10.1007/978-1-0716-3523-0_6.

Eudragit FS Microparticles Containing Bacteriophages, Prepared by Spray-Drying for Oral Administration.

Tabare E, Dauchot T, Cochez C, Glonti T, Antoine C, Laforet F Pharmaceutics. 2023; 15(6).

PMID: 37376051 PMC: 10305712. DOI: 10.3390/pharmaceutics15061602.

Advancements in the Use of Bacteriophages to Combat the Kiwifruit Canker Phytopathogen pv. .

Luo J, Dai D, Lv L, Ahmed T, Chen L, Wang Y Viruses. 2022; 14(12).

PMID: 36560706 PMC: 9785728. DOI: 10.3390/v14122704.

Enhancing the Stability of Bacteriophages Using Physical, Chemical, and Nano-Based Approaches: A Review.

Wdowiak M, Paczesny J, Raza S Pharmaceutics. 2022; 14(9).

PMID: 36145682 PMC: 9502844. DOI: 10.3390/pharmaceutics14091936.

References

Carrigy N, Liang L, Wang H, Kariuki S, Nagel T, Connerton I . Trileucine and Pullulan Improve Anti-Campylobacter Bacteriophage Stability in Engineered Spray-Dried Microparticles. Ann Biomed Eng. 2019; 48(4):1169-1180. DOI: 10.1007/s10439-019-02435-6. View

Ziaee A, Albadarin A, Padrela L, Femmer T, OReilly E, Walker G . Spray drying of pharmaceuticals and biopharmaceuticals: Critical parameters and experimental process optimization approaches. Eur J Pharm Sci. 2018; 127:300-318. DOI: 10.1016/j.ejps.2018.10.026. View

McAdams D, Chen D, Kristensen D . Spray drying and vaccine stabilization. Expert Rev Vaccines. 2012; 11(10):1211-9. DOI: 10.1586/erv.12.101. View

Chang R, Wong J, Mathai A, Morales S, Kutter E, Britton W . Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection. Eur J Pharm Biopharm. 2017; 121:1-13. PMC: 5650506. DOI: 10.1016/j.ejpb.2017.09.002. View

Simon A, Amaro M, Cabral L, Healy A, de Sousa V . Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate. Int J Pharm. 2016; 501(1-2):124-38. DOI: 10.1016/j.ijpharm.2016.01.066. View

Aquino R, Prota L, Auriemma G, Santoro A, Mencherini T, Colombo G . Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm. 2012; 426(1-2):100-107. DOI: 10.1016/j.ijpharm.2012.01.026. View

Focaroli S, Mah P, Hastedt J, Gitlin I, Oscarson S, Fahy J . A Design of Experiment (DoE) approach to optimise spray drying process conditions for the production of trehalose/leucine formulations with application in pulmonary delivery. Int J Pharm. 2019; 562:228-240. PMC: 6562166. DOI: 10.1016/j.ijpharm.2019.03.004. View

Emami F, Vatanara A, Park E, Na D . Drying Technologies for the Stability and Bioavailability of Biopharmaceuticals. Pharmaceutics. 2018; 10(3). PMC: 6161129. DOI: 10.3390/pharmaceutics10030131. View

Szermer-Olearnik B, Drab M, Makosa M, Zembala M, Barbasz J, Dabrowska K . Aggregation/dispersion transitions of T4 phage triggered by environmental ion availability. J Nanobiotechnology. 2017; 15(1):32. PMC: 5404661. DOI: 10.1186/s12951-017-0266-5. View

10.

Vandenheuvel D, Meeus J, Lavigne R, Van den Mooter G . Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix. Int J Pharm. 2014; 472(1-2):202-5. DOI: 10.1016/j.ijpharm.2014.06.026. View

11.

Mah P, OConnell P, Focaroli S, Lundy R, OMahony T, Hastedt J . The use of hydrophobic amino acids in protecting spray dried trehalose formulations against moisture-induced changes. Eur J Pharm Biopharm. 2019; 144:139-153. PMC: 6938683. DOI: 10.1016/j.ejpb.2019.09.014. View

12.

Serwer P, Hayes S, Lieman K . Aggregates of bacteriophage 0305phi8-36 seed future growth. Virol J. 2007; 4:131. PMC: 2222632. DOI: 10.1186/1743-422X-4-131. View

13.

Vandenheuvel D, Singh A, Vandersteegen K, Klumpp J, Lavigne R, Van den Mooter G . Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur J Pharm Biopharm. 2013; 84(3):578-82. DOI: 10.1016/j.ejpb.2012.12.022. View

14.

Mattle M, Crouzy B, Brennecke M, Wigginton K, Perona P, Kohn T . Impact of virus aggregation on inactivation by peracetic acid and implications for other disinfectants. Environ Sci Technol. 2011; 45(18):7710-7. DOI: 10.1021/es201633s. View

15.

Lechanteur A, Evrard B . Influence of Composition and Spray-Drying Process Parameters on Carrier-Free DPI Properties and Behaviors in the Lung: A review. Pharmaceutics. 2020; 12(1). PMC: 7022846. DOI: 10.3390/pharmaceutics12010055. View

16.

Chang R, Kwok P, Khanal D, Morales S, Kutter E, Li J . Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization. Bioeng Transl Med. 2020; 5(2):e10159. PMC: 7237144. DOI: 10.1002/btm2.10159. View

17.

Matinkhoo S, Lynch K, Dennis J, Finlay W, Vehring R . Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J Pharm Sci. 2011; 100(12):5197-205. DOI: 10.1002/jps.22715. View

18.

Kutter E . Phage host range and efficiency of plating. Methods Mol Biol. 2008; 501:141-9. DOI: 10.1007/978-1-60327-164-6_14. View

19.

Breidenstein E, de la Fuente-Nunez C, Hancock R . Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011; 19(8):419-26. DOI: 10.1016/j.tim.2011.04.005. View

20.

Pramod K, Abu Tahir M, Charoo N, Ansari S, Ali J . Pharmaceutical product development: A quality by design approach. Int J Pharm Investig. 2016; 6(3):129-38. PMC: 4991121. DOI: 10.4103/2230-973X.187350. View